abeonatherapeutics.com (ABEO) Quarterly EPS earnings growth

Symbol and logo of brand abeonatherapeutics.com (ABEO)

Abeona Therapeutics (ABEO) maintains high profitability based on a unique skin gene therapy ecosystem that creates an indispensable environment for clinics. Comparable quarterly EPS growth is reflected in the current trend, where the indicator stands at 12.50. Management has successfully overcome manufacturing challenges and is finalizing drug registrations. The potential for monopoly pricing power over its products now depends directly on final FDA regulatory approval.

ABEO: Abeona Therapeutics Inc. Year-over-year earnings per one share growth for the last 12 months 07/04/2022 - 11/17/2026

abeonatherapeutics.com (ABEO) - metric breakdowns and financial figures

Initial company analysis:Abeona Therapeutics
Flagship merchandise of Abeona Therapeutics

This indicator measures the rate of change in net earnings per share, identifying the gap between market expectations and the issuer's actual performance. By analyzing the percentage change in quarterly EPS, an investor can observe profitability dynamics in real time. The current value of 12.50 reflects the result of comparing current earnings with the same period last year. For Abeona Therapeutics (ABEO), this metric depends on the volume of government grants and insurance payments. Such cash flows are critical when developing costly drugs for the treatment of orphan diseases.

Who Abeona Therapeutics competes with

VRTX: Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months Alnylam Inc. (ALNY)|INSM (Insmed) - Quarterly EPS earnings growth|Year-over-year earnings per share growth for the last 12 months UTHR (United Therapeutics Corporation)|Year-over-year net earnings per share growth for the last 12 months BMRN (BioMarin)|BBIO (BridgeBio Pharma) - Year-over-year earnings per one share growth for the last 12 months|Quarterly EPS earnings growth BGM (BGM Group Ltd)|COGT (Cogent Bio) - Year-over-year net earnings per share trend for the last twelve months|Xeris Biopharma - Quarterly EPS earnings growth|Year-over-year earnings per one share growth for the last 12 months KROS (Keros Therapeutics)|ARCT: Quarterly EPS earnings growth|Eton Pharmaceuticals Inc (ETON) - Quarterly EPS earnings growth|Year-over-year earnings per share growth for the last twelve months Kamada Corp|FULC: Year-over-year earnings per one share growth for the last 12 months|Year-over-year earnings per share growth for the last twelve months Mereo BioPharma Group (MREO)|Quarterly EPS earnings growth protalix.com (PLX)|Quarterly EPS earnings growth PLRX (Pliant Therapeutics Inc)|Quarterly EPS earnings growth Applied Therapeutics APLT|RNTX - Year-over-year earnings per share growth for the last twelve months|Net earnings per share growth for the trailing year gelteq.com (GELS)|AYTU (aytubio.com) - Year-over-year net earnings per share growth for the last 12 months|Chemomab Therapeutics Ltd - Year-over-year earnings per one share growth for the last 12 months|Year-over-year net earnings per share growth for the last 12 months SRXH|Year-over-year earnings per share growth for the last twelve months PLRZ|Quarterly EPS earnings growth AEZS|Year-over-year earnings per share growth for the last twelve months CYTH (Cyclo Therapeutics, Inc)|Inozyme Pharma - Year-over-year net earnings per share growth for the last 12 months|Reneo Pharmaceuticals, Inc. (RPHM) - Earnings per share growth in annualized terms for the last twelve months|COSCIENS Bio - Quarterly EPS earnings growth